替尔泊肽出阵、司美格鲁肽守擂 GLP-1制剂中国“霸主”之争鸣锣

每日经济新闻
07 Jan

激战正酣的司美格鲁肽制剂和替尔泊肽制剂终于“打”到了国内市场。近日,礼来公司在官方微信号宣布替尔泊肽注射液(中文商品名为穆峰达)正式于国内上市,适应症涵盖2型糖尿病患者血糖控制和超重/肥胖人群的体重控制。  由于适应症有所重合,替尔泊肽和司美格鲁肽一直被视为竞争对手。记者注意到,在去年底,礼来曾发布一项“头对头”(指非安慰剂对照研究)试验的结果,称替尔泊肽减重效果优于司美格鲁肽。 图片来源:微信...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10